Table 3.
Latent Epstein-Barr virus products interacting with the cellular epigenetic regulatory machinery
| Latency product | Cellular partner | Putative outcome of the interaction |
|---|---|---|
| EBNA1 | EBNA1 binding site | site-specific demethylation of DNA; activation of adjacent genes; |
| EBNA2 | histone acetyltransferases (p300, CBP, PCAF) | transactivation of genes; |
| EBNA3C (EBNA6) | prothymosin alpha, p300; histone deacetylases (HDAC1 & 2) | modulating EBNA2-mediated transactivation |
| EBNA-LP (EBNA5) | histone deacetylase 4 (HDAC4) | dispacement of HDAC4 from EBNA2-activated promoters; coactivation |
| LMP1 | DNA methyltransferases DNMT1, 3a, 3b; | hypermethylation mediated silencing of promoters; |
| Bmi-1 (a component of PRC1); | silencing of B cell specific and tumor suppressor genes; | |
| marking a set of promoters for de novo methylation by DNMTases; | ||
| up-regulation of transcription (STAT-1, c-MET, HK); | ||
| via the NF-κB pathway: microRNA coding genes | alteration of miR-146a and miR-1 level; modulation of cellular mRNA levels |